Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...
Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...
Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...
The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.
Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027. Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be rep ...
New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...
PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...
From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results